healthcaretrends

The global multiplex assays market is projected to reach USD 3.35 Billion in 2023 from USD 2.17 Billion in 2017, at CAGR of 7.5%. In the current market scenario, there is a growing demand for multiplex assays. The major factors driving the growth of the market include the adoption of Companion Diagnostics for increasing the safety & efficacy of therapies and the advantages of multiplex assays over conventional singleplex assays.

Download PDF Brochure @
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=61593314

Opportunity: Monitoring of biosimilars in autoimmune diseases

Anti-TNF-alpha biologics are proving to be an effective treatment for autoimmune diseases, such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). With the increasing healthcare costs as well as patent expirations, the number of R&D activities focusing on the development of biosimilars have increased over the last few years. The launch of biosimilars in the market is increasing the need for the better understanding of potential differences in biosimilar immunogenicity as well as their safety and efficacy profiles as compared to their precursors. For instance, TNF-alpha blockers, such as infliximab and adalimumab, both can trigger immunogenicity responses and researchers have hypothesized that their biosimilars drugs (CT-P13) may also promote immunogenicity. Therefore, it is vital to develop methods for the TDM of biosimilar drugs for autoimmune diseases to ensure effective patient care.

Driver: Use of TDM in traditional anticancer therapies

TDM provides valuable guidance for the dose adjustment of antibiotics, immunosuppressants, antiepileptics, and other drugs. However, its use in traditional anticancer therapies has been limited. The requirement of multiple blood samples to adequately define the systemic exposure of anticancer drugs is the major issue encountered while testing for anticancer therapies.

Drugs in blood samples have a short elimination half-life and are given by intermittent intravenous injections; this makes the entire monitoring process difficult to analyze. However, newer targeted anticancer therapies have different pharmacokinetic (PK) and dosing characteristics as compared with traditional cytotoxic drugs. Owing to this, it is now possible to estimate the steady-state drug exposure with a single trough-level measurement. Recent evidence indicates that certain PK parameters, including trough levels, are correlated with clinical outcomes for many cytotoxic agents, including imatinib, sunitinib, rituximab, and cetuximab.

Although current evidence is not sufficient to make TDM a compulsory practice, investigations with encouraging results will have a practical place in the clinical care of patients with cancer. With the increasing incidence of cancer and focus on reducing the adverse effects of drugs, the monitoring of antineoplastic drugs is expected to gain more importance in the treatment of cancer.

North America is expected to account for the largest market share

North America is expected to account for the largest share of this market, followed by Europe. Growth in the North American market is mainly driven by the increasing per capita healthcare expenditure and the presence of technologically advanced healthcare infrastructure in the region. Initiatives taken by different government associations are also anticipated to boost market growth in the coming years.

Request Sample Pages @
https://www.marketsandmarkets.com/requestsampleNew.asp?id=61593314

Key Players:

Abbott Laboratories, Hoffmann-La Roche, Siemens Healthineers, Thermo Fisher Scientific, Danaher Corporation, Bio-Rad Laboratories, Biomérieux, Bühlmann Laboratories, Sekisui Medical, Randox Laboratories.